FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1897524963> ?p ?o ?g. }

• W1897524963 endingPage "84" @default.
• W1897524963 startingPage "873" @default.
• W1897524963 abstract "The taxanes, paclitaxel (PTX) and docetaxel (DTX), belong to a novel class of anticancer drugs that stabilize microtubules and lead to tumor cell death. While both agents are widely used for the treatment of lung, breast, and ovarian cancer, many tumor types are refractory or develop resistance to these drugs. We describe here a novel analogue of DTX, designated MAC-321 [Microtubule/Apoptosis/Cytotoxic: 5beta, 20-epoxy-1, 2alpha-, 4-, 7beta-, 10beta-, 13alpha-hexahydroxytax-11-en-9-one 4 acetate 2 benzoate 7-propionate 13-ester with (2R,3S)-N-tertbutoxycarbonyl-3-(2-furyl)isoserine], that overcomes P-glycoprotein-mediated resistance to PTX and DTX in preclinical model systems. Similar to PTX or DTX, MAC-321 enhanced the rate of tubulin polymerization in vitro and caused the bundling of microtubules in cells. MAC-321 inhibited proliferation of a panel of 14 tumor cell lines with minimal variation in potency (IC(50) = 2.2 +/- 1.4 nM; range = 0.6-5.3 nM). Unlike PTX or DTX, the IC(50) of MAC-321 did not vary in cells that expressed low to moderate levels of P-glycoprotein. Even under extraordinary conditions in KB-V1 cells, which highly overexpress P-glycoprotein, resistance to MAC-321 was 80-fold compared with that of PTX (1400-fold) and DTX (670-fold). In addition, equivalent or less resistance to MAC-321 compared with PTX or DTX was observed in four cell lines that contain distinct point mutations within the taxane-binding site of beta-tubulin. Most importantly, MAC-321 displayed superior in vivo efficacy because: (a) MAC-321 either partially or completely inhibited tumor growth in three tumor models that overexpressed P-glycoprotein and were resistant to PTX; and (b) unlike PTX or DTX, MAC-321 was highly effective when given orally. MAC-321 was also highly effective when given as single i.v. dose. Our findings suggest that MAC-321, which is currently under clinical evaluation, may have broad therapeutic value." @default.
• W1897524963 created "2016-06-24" @default.
• W1897524963 creator A5012621685 @default.
• W1897524963 creator A5019947480 @default.
• W1897524963 creator A5026218835 @default.
• W1897524963 creator A5033020659 @default.
• W1897524963 creator A5039115512 @default.
• W1897524963 creator A5044451793 @default.
• W1897524963 creator A5047783801 @default.
• W1897524963 creator A5061081453 @default.
• W1897524963 creator A5081024363 @default.
• W1897524963 creator A5084686390 @default.
• W1897524963 creator A5088664989 @default.
• W1897524963 date "2003-09-01" @default.
• W1897524963 modified "2023-09-28" @default.
• W1897524963 title "MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo." @default.
• W1897524963 cites W1713351558 @default.
• W1897524963 cites W1907962006 @default.
• W1897524963 cites W190801549 @default.
• W1897524963 cites W1929450387 @default.
• W1897524963 cites W196162305 @default.
• W1897524963 cites W1965959092 @default.
• W1897524963 cites W1968965382 @default.
• W1897524963 cites W1971182486 @default.
• W1897524963 cites W1984820569 @default.
• W1897524963 cites W1985750428 @default.
• W1897524963 cites W1988351341 @default.
• W1897524963 cites W1995277744 @default.
• W1897524963 cites W1996691278 @default.
• W1897524963 cites W2006434892 @default.
• W1897524963 cites W2014348578 @default.
• W1897524963 cites W2021885202 @default.
• W1897524963 cites W2037490361 @default.
• W1897524963 cites W2039647828 @default.
• W1897524963 cites W2043478531 @default.
• W1897524963 cites W2044695226 @default.
• W1897524963 cites W2045862609 @default.
• W1897524963 cites W2056457054 @default.
• W1897524963 cites W2067107748 @default.
• W1897524963 cites W2067299834 @default.
• W1897524963 cites W2073533584 @default.
• W1897524963 cites W2075677078 @default.
• W1897524963 cites W2089248551 @default.
• W1897524963 cites W2099149475 @default.
• W1897524963 cites W2102286060 @default.
• W1897524963 cites W2106787323 @default.
• W1897524963 cites W2107607807 @default.
• W1897524963 cites W2108244474 @default.
• W1897524963 cites W2108929767 @default.
• W1897524963 cites W2110484017 @default.
• W1897524963 cites W2117888794 @default.
• W1897524963 cites W2122631316 @default.
• W1897524963 cites W2135538021 @default.
• W1897524963 cites W2138993111 @default.
• W1897524963 cites W2139658812 @default.
• W1897524963 cites W2141494978 @default.
• W1897524963 cites W2141795847 @default.
• W1897524963 cites W2145555831 @default.
• W1897524963 cites W2158749015 @default.
• W1897524963 cites W2162149445 @default.
• W1897524963 cites W2162960688 @default.
• W1897524963 cites W2165629556 @default.
• W1897524963 cites W2167032192 @default.
• W1897524963 cites W2171373345 @default.
• W1897524963 cites W2334321795 @default.
• W1897524963 cites W2402502498 @default.
• W1897524963 cites W2467547219 @default.
• W1897524963 cites W572492997 @default.
• W1897524963 cites W2147051864 @default.
• W1897524963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14555706" @default.
• W1897524963 hasPublicationYear "2003" @default.
• W1897524963 type Work @default.
• W1897524963 sameAs 1897524963 @default.
• W1897524963 citedByCount "19" @default.
• W1897524963 countsByYear W18975249632013 @default.
• W1897524963 countsByYear W18975249632017 @default.
• W1897524963 countsByYear W18975249632018 @default.
• W1897524963 countsByYear W18975249632019 @default.
• W1897524963 countsByYear W18975249632021 @default.
• W1897524963 crossrefType "journal-article" @default.
• W1897524963 hasAuthorship W1897524963A5012621685 @default.
• W1897524963 hasAuthorship W1897524963A5019947480 @default.
• W1897524963 hasAuthorship W1897524963A5026218835 @default.
• W1897524963 hasAuthorship W1897524963A5033020659 @default.
• W1897524963 hasAuthorship W1897524963A5039115512 @default.
• W1897524963 hasAuthorship W1897524963A5044451793 @default.
• W1897524963 hasAuthorship W1897524963A5047783801 @default.
• W1897524963 hasAuthorship W1897524963A5061081453 @default.
• W1897524963 hasAuthorship W1897524963A5081024363 @default.
• W1897524963 hasAuthorship W1897524963A5084686390 @default.
• W1897524963 hasAuthorship W1897524963A5088664989 @default.
• W1897524963 hasConcept C121608353 @default.
• W1897524963 hasConcept C126322002 @default.
• W1897524963 hasConcept C150903083 @default.
• W1897524963 hasConcept C154317977 @default.
• W1897524963 hasConcept C185592680 @default.
• W1897524963 hasConcept C190283241 @default.
• W1897524963 hasConcept C202751555 @default.

• next